Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

A Multi-Center, Open Label, Phase I/II Study to Assess the Safety and Efficacy of Tenalisib Given in Combination with Romidepsin in Patients with Relapsed/Refractory T-Cell Lymphoma

Swami P. Iyer, MD, Auris Huen, MD, Bradley Haverkos, MD MPH, MS, Weiyun Z. Ai, Craig Okada, MD PhD, Timothy M. Kuzel, MD, Mary Jo Lechowicz, MD, Juan Pablo Alderuccio, MD, Ann Mohrbacher, MD, Don A. Stevens, MD, Ryan A. Wilcox, MD, Tatyana A. Feldman, MD, Suchitra Sundaram, MD, Deepa Jagadeesh, MDMPH, Nishitha Reddy, MD MSCI, Kasi Viswanath Routhu, PhD, Prajak Barde, MD, Ajit Mohanchandran Nair, PhD

Blood (2020) 136 (Supplement 1): 8–10.

https://doi.org/10.1182/blood-2020-136018

Published: 2020

Journal Articles

A Phase 1a/1b Trial of ST-001, a Fenretinide Phospholipid Suspension for 4-Hour Intravenous Infusion in Relapsed/Refractory T-Cell Non-Hodgkin's Lymphoma

Ayad Al-Katib, MD, Timothy M. Kuzel, MD, Ralph Parchment, PhD

Blood (2019) 134 (Supplement_1): 4041.

https://doi.org/10.1182/blood-2019-127278

Published: 2019

Journal Articles

First Report of Severe Folate Deficiency in Women Treated with Olaparib for Relapsed Ovarian Cancer

Jamile M. Shammo, MD, Lydia Usha, MD, Kristin Richardson, MD, Elizabeth Jane Elliott, BS, DO, Parameswaran Venugopal, MD, Timothy M. Kuzel, MD, Melody Cobleigh, MD, Summer Dewdney, MD

Blood (2017) 130 (Supplement 1): 4748.

https://doi.org/10.1182/blood.V130.Suppl_1.4748.4748

Published: 2017

Journal Articles

Updated Analyses of the International, Open-Label, Randomized, Phase 3 Alcanza Study: Longer-Term Evidence for Superiority of Brentuximab Vedotin Versus Methotrexate or Bexarotene for CD30-Positive Cutaneous T-Cell Lymphoma (CTCL)

Blood (2017) 130 (Supplement 1): 1509.

https://doi.org/10.1182/blood.V130.Suppl_1.1509.1509

Published: 2017

Journal Articles

A Dose Finding Lead-in Study of E7777 (Diphtheria toxin fragment-Interleukin-2 Fusion Protein) in Persistent or Recurrent Cutaneous T-Cell Lymphoma (CTCL)

Madeleine Duvic, MD, Timothy M Kuzel, MD, Nam H. Dang, MD PhD, Miles Prince, MD FRACP, FRCPA, Tatyana Feldman, MD, Francine M. Foss, MD, Matthew Guo, PhD, Lone Harild Ottesen, MD PhD, Chean Eng Ooi, PhD, Youn H Kim, MD

Blood (2014) 124 (21): 3097.

https://doi.org/10.1182/blood.V124.21.3097.3097

Published: 2014

Journal Articles

The Systemic Effects of Vorinostat in Patients (Pts) with Cutaneous T-Cell Lymphoma (CTCL): Post-Hoc Analyses in Pts with High Blood Tumor Burden.

Madeleine Duvic, MD, Youn H Kim, MD, Timothy M Kuzel, MD, Theresa R Pacheco, MD, Francine M Foss, Sareeta Parker, Syed Rizvi, Cong Chen, Jean Marie Arduino, ScD, Elise A. Olsen, MD

Blood (2009) 114 (22): 1709.

https://doi.org/10.1182/blood.V114.22.1709.1709

Published: 2009

Journal Articles

Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) Provides Prolonged Clinical Benefit to Advanced Cutaneous T-Cell Lymphoma Patients: Updated Results of the Phase IIb Multicenter Clinical Trial.

Madeleine Duvic, MD, Youn H. Kim, MD, Timothy M. Kuzel, MD, Theresa R. Pacheco, MD, Francine M. Foss, MD, Sareeta Parker, MD, Stanley R. Frankel, MD, Cong Chen, PhD, Justin L. Ricker, MD, PhD, Jean Marie Arduino, PhD, Sophia Randolph, MD, PhD, Victoria M. Richon, PhD, Elise A. Olsen, MD

Blood (2006) 108 (11): 399.

https://doi.org/10.1182/blood.V108.11.399.399

Published: 2006

Journal Articles

Concurrent Treatment with Denileukin Diftitox (DD) To Deplete T-Regulatory Cells Enhances Rebound Lymphocytosis and Eosinophilia in Patients Treated with High-Dose IL-2 (HDIL-2) for Metastatic Renal Cell Cancer (MRCC).

Adi Gidron, MD, John Eklund, MD, Brenda Martone, RN, MSN, Alfred W. Rademaker, PhD, Charles Goolsby, PhD, Laura Marszalek, Timothy M. Kuzel, MD

Blood (2006) 108 (11): 1729.

https://doi.org/10.1182/blood.V108.11.1729.1729

Published: 2006

Journal Articles

Alemtuzumab (Campath-1H) in Patients with Erythrodermic Cutaneous T-Cell Lymphoma (E-CTCL): The Northwestern University Experience.

Christiane Querfeld, MD, Steven T. Rosen, MD, Joan Guitart, MD, Brenda Martone, RN, MSN, Alfred Rademaker, PhD, Timothy M. Kuzel, MD

Blood (2006) 108 (11): 2732.

https://doi.org/10.1182/blood.V108.11.2732.2732

Published: 2006

Journal Articles

Preliminary Results of a Phase II Study of CC-5013 (Lenalidomide, Revlimid®) in Patients with Cutaneous T-Cell Lymphoma.

Christiane Querfeld, MD, Timothy M. Kuzel, MD, Joan Guitart, MD, Steven T. Rosen, MD

Blood (2005) 106 (11): 3351.

https://doi.org/10.1182/blood.V106.11.3351.3351

Published: 2005

Journal Articles

FDA Policies Should Be Amended To Allow Pharmaceutical Manufacturers To Disseminate Information Regarding Potentially Fatal Toxicities That Occur with Off-Label Use of Oncology Agents: A Policy Recommendation Based on Review of Thalidomide-Associated Thromboembolism Cases by the RADAR Project.

Andrew M. Evens, DO, Martin S. Tallman, MD, Seema Singhal, MD, June M. McKoy, MD, JD, E. Allison Lyons, BA, Dennis W. Raisch, PhD, Paul R. Yarnold, PhD, Hau Kwaan, MD, Timothy M. Kuzel, MD, Jayesh Mehta, MD, Charles L. Bennett, MD, PhD

Blood (2004) 104 (11): 265.

https://doi.org/10.1182/blood.V104.11.265.265

Published: 2004

Journal Articles

Long-Term Follow-Up of 98 Cases of Recombinant Human Erythropoietin (epoetin) Induced Pure Red Cell Aplasia (PRCA): Outcomes and Treatment Data from the Research on Adverse Drug Reactions and Reports (RADAR) Program.

Kenneth R. Carson, MD, Stephen A. Klinge, BA, Steven M. Belknap, MD, June M. McKoy, MD, JD, MPH, Dennis W. Raisch, PhD, Martin S. Tallman, MD, Timothy M. Kuzel, MD, Andrew M. Evans, MD, Benjamin Kim, MD, Paul R. Yarnold, PhD, Elizabeth A. Lyons, BA, Charles L. Bennett, MD, PhD

Blood (2004) 104 (11): 5320.

https://doi.org/10.1182/blood.V104.11.5320.5320

Published: 2004

NARROW

A Multi-Center, Open Label, Phase I/II Study to Assess the Safety and Efficacy of Tenalisib Given in Combination with Romidepsin in Patients with Relapsed/Refractory T-Cell Lymphoma

A Phase 1a/1b Trial of ST-001, a Fenretinide Phospholipid Suspension for 4-Hour Intravenous Infusion in Relapsed/Refractory T-Cell Non-Hodgkin's Lymphoma

First Report of Severe Folate Deficiency in Women Treated with Olaparib for Relapsed Ovarian Cancer

Updated Analyses of the International, Open-Label, Randomized, Phase 3 Alcanza Study: Longer-Term Evidence for Superiority of Brentuximab Vedotin Versus Methotrexate or Bexarotene for CD30-Positive Cutaneous T-Cell Lymphoma (CTCL)

A Dose Finding Lead-in Study of E7777 (Diphtheria toxin fragment-Interleukin-2 Fusion Protein) in Persistent or Recurrent Cutaneous T-Cell Lymphoma (CTCL)

The Systemic Effects of Vorinostat in Patients (Pts) with Cutaneous T-Cell Lymphoma (CTCL): Post-Hoc Analyses in Pts with High Blood Tumor Burden.

Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) Provides Prolonged Clinical Benefit to Advanced Cutaneous T-Cell Lymphoma Patients: Updated Results of the Phase IIb Multicenter Clinical Trial.

Concurrent Treatment with Denileukin Diftitox (DD) To Deplete T-Regulatory Cells Enhances Rebound Lymphocytosis and Eosinophilia in Patients Treated with High-Dose IL-2 (HDIL-2) for Metastatic Renal Cell Cancer (MRCC).

Alemtuzumab (Campath-1H) in Patients with Erythrodermic Cutaneous T-Cell Lymphoma (E-CTCL): The Northwestern University Experience.

Preliminary Results of a Phase II Study of CC-5013 (Lenalidomide, Revlimid®) in Patients with Cutaneous T-Cell Lymphoma.

FDA Policies Should Be Amended To Allow Pharmaceutical Manufacturers To Disseminate Information Regarding Potentially Fatal Toxicities That Occur with Off-Label Use of Oncology Agents: A Policy Recommendation Based on Review of Thalidomide-Associated Thromboembolism Cases by the RADAR Project.

Long-Term Follow-Up of 98 Cases of Recombinant Human Erythropoietin (epoetin) Induced Pure Red Cell Aplasia (PRCA): Outcomes and Treatment Data from the Research on Adverse Drug Reactions and Reports (RADAR) Program.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only